Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: artificial intelligence aided therapeutics - Recursion Pharmaceuticals

Next Previous
Drug Profile

Research programme: artificial intelligence aided therapeutics - Recursion Pharmaceuticals

Alternative Names: Inborn genetic disorder therapeutics - Recursion Pharmaceuticals; REC-0000355; REC-0000382; REC-0000716; REC-0001117; REC-0001202; REC-0001317; REC-0001571; REC-0001982

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Recursion Pharmaceuticals
  • Class Anti-inflammatories; Antibacterials; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Cardiovascular disorders; Charcot-Marie-Tooth disease; Clostridium difficile infections; Darier disease; Eye disorders; Haematological disorders; Inborn error metabolic disorders; Inflammation; Neurofibromatosis 2; Neurological disorders; Neuronal ceroid lipofuscinosis

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for preclinical development in Cancer in USA
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in USA
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top